With a mission to cure Duchenne muscular dystrophy
CureDuchenne breaks the traditional charitable mold and balances passion with business acumen. Our innovative venture philanthropy model funds groundbreaking research, early diagnosis and treatment access. With pioneering education and support programs, our organization drives real change for those with Duchenne muscular dystrophy and their loved ones.
Making an Impact
Your Dollar Counts
90% of every dollar goes to research and mission critical programs.
Funding Critical Clinical Trials
12 projects funded by CureDuchenne have progressed to clinical trials.
Making an Impact
We’ve raised over $50 million for research, education and care.
Accelerating a Cure
CureDuchenne contributed early funding for the first FDA-approved Duchenne drug.
Working Towards the Future
Our model has leveraged $2.3 billion in follow-on funding for future programs from investors and biotech companies.
Duchenne is a devastating muscle disease.
Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy, occurring in approximately 1:5,000 male births. Those affected with Duchenne lose their ability to walk, feed themselves, breathe independently and succumb to heart failure. But there’s hope through new pharmacological and gene-based therapies. You can help make a difference.
The CureDuchenne 2019 FUTURES Time Capsule Video
The CureDuchenne Time Capsule Video is a beautiful compilation of interviews conducted at the 2019 FUTURES Conference in Anaheim, CA. We asked families to share their stories with us, as […]
“We were very impressed with CureDuchenne’s portfolio and how their funding is put towards research. We wanted the money we raise to go 100% towards research in clinical trials…”
Braedan’s Bridge began the journey in 2011 shortly after our own son, Braedan was diagnosed with Duchenne muscular dystrophy. As most parents, our story is very similar. One day you […]
“We didn’t know anything about Duchenne and felt isolated that there was no one we could turn to, other than the doctors or the internet for advice, inspiration, or HOPE…”
August 8, 2011 was the day we first heard the word Duchenne. Every moment of that day is etched in my memory. We were hit out of the blue with […]
“We joined CureDuchenne more than a decade ago in their mission to find a cure for Duchenne. We partnered with CureDuchenne because they are steadfast in identifying and funding promising research…”
When our two sons Timothy, 13, and Andrew, 10, were diagnosed with Duchenne muscular dystrophy there was little hope. We were told there was no cure or treatment and that […]
“My son Aiden was diagnosed with Duchenne Muscular Dystrophy on June 2, 2015. He was 3 at the time. That date will forever be etched in my mind…”
My heart was beating so fast, anxiety creeping into my body. It felt like everything stopped. I can’t remember her exact words, but I distinctly remember the fear that took […]
“As part of our journey, our family has partnered with CureDuchenne, a national non-profit that is leading the effort to accelerate the drug approval process on potential life-saving therapies…”
Our Journey Deaing with Duchenne Our son Joshua was born in 2007. Joshua, our oldest son, is an amazing and fun-loving boy. He was diagnosed with Duchenne Muscular Dystrophy in 2013. […]
“The CureDuchenne Cares program is one of the most impactful courses I’ve ever taken. This program has empowered me to become the best physical therapist that a Duchenne patient and their family needs…”
Every Duchenne parent wants to know that their child is in good hands with their medical team. Physical therapy is an important part of that medical team, and Texas physical […]
- CUREDUCHENNE LAUNCHES NEXT-GENERATION DATA-SHARING PLATFORM TO ACCELERATE A CURE FOR DUCHENNE AND BECKER MUSCULAR DYSTROPHYJune 18, 2021
- Exercise and Duchenne Muscular Dystrophy: Part 2June 7, 2021
- Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD StudyJune 1, 2021
- Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial Process MaterialMay 18, 2021
- Don’t Miss CureDuchenne at the Gene Therapy for Muscular Disorders EventMay 14, 2021